{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-458486","form_type":"8-K","ticker":"SCTX","cik":"0001853921","company_name":"Scribe Therapeutics, Inc.","filed_at":"2026-11-12T21:20:14+00:00","discovered_at":"2026-11-12T21:21:09.565023+00:00","generated_at":"2026-11-12T21:21:16.288995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Scribe Therapeutics Q3 2026 net loss $9.9M ($0.68/sh); $174.2M cash funds operations into 1H 2029","bullets":["Net loss $9.9M ($0.68 per basic and diluted share) vs $6.5M net loss in Q2 2026; R&D $8.3M, G&A $4.2M, collaboration revenue $1.6M.","Cash, equivalents and marketable securities $174.2M at Sept 30, 2026 vs $43.0M at June 30, after ~$140.2M net IPO/private placement proceeds; runway into 1H 2029.","STX-1150 Phase 1 in elevated LDL-C ongoing; safety, tolerability and LDL-C data from single ascending dose expected 1H 2027; NHP data showed >50% LDL-C cut at 0.75 mg/kg for two years.","Expanded Sanofi collaboration to include ELXR epigenetic silencing technology, adding to XE gene editing and extending Sanofi's target nomination period; no financial terms disclosed.","July 2026 IPO upsized and priced at high end; ~$155.5M gross proceeds including underwriters' option and concurrent Sanofi private placement at the IPO price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-458486","json":"https://secwatch.observer/filing/0001193125-26-458486.json","markdown":"https://secwatch.observer/filing/0001193125-26-458486.md","text":"https://secwatch.observer/filing/0001193125-26-458486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853921/000119312526458486/0001193125-26-458486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853921/000119312526458486/sctx-20261112.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-12T21:21:16.288995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}